Business Wire: United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
Yahoo Finance: Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
News Medical: Qureight Vascul8 model for pulmonary vascular disorders validated in peer-reviewed study, offering potential to improve treatment options and patient outcomes following surgery
Qureight Vascul8 model for pulmonary vascular disorders validated in peer-reviewed study, offering potential to improve treatment options and patient outcomes following surgery
Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is ...
The American Journal of Managed Care: How Diabetes Impacts Pulmonary Vascular Dysfunction and Fibrosis
EurekAlert!: ATS Research Program announces 2025 Early Career Investigator Awards in Pulmonary Vascular Disease, sponsored by Johnson & Johnson
ATS Research Program announces 2025 Early Career Investigator Awards in Pulmonary Vascular Disease, sponsored by Johnson & Johnson
EurekAlert!: Chronic thromboembolic pulmonary vascular disease and left heart disease are not mutually exclusive
Chronic thromboembolic pulmonary vascular disease and left heart disease are not mutually exclusive
Please provide your email address to receive an email when new articles are posted on . Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic ...